Medication Issues in Older Individuals With CKD

Advances in Chronic Kidney Disease

Volumn 17, Issue 4, 2010, Pages 320-328

  Rifkin, Dena E ^a   Winkelmayer, Wolfgang C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug interaction; Effectiveness; Geriatrics; Pharmacoepidemiology; Prescription drugs; Safety; Utilization

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORDIAZEPOXIDE; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; LORAZEPAM; LOSARTAN; METAXALONE; METHOCARBAMOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXAZEPAM; PRAVASTATIN; RECOMBINANT ERYTHROPOIETIN; ROFECOXIB; TEMAZEPAM;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DELIRIUM; GERIATRIC CARE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

AGED; AGED, 80 AND OVER; AGING; ANALGESICS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DRUG UTILIZATION; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; PRESCRIPTION DRUGS; PSYCHOTROPIC DRUGS; RISK FACTORS; UNITED STATES;

EID: 77953709237     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.03.005     Document Type: Review

References (77)

1. Centers for Disease Control and Prevention, Public health and aging: Trends in aging-United States and worldwide. MMWR Morb Mortal Wkly Rep 52 (2003) 101-106
2. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007) 2038-2047
3. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 2 Suppl 1 (2002) S1-S266
4. Keith D.S., Nicholas G.A., Gullion C.M., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 (2004) 659-663
5. Prevalence of selected conditions by age and sex: United States, 1984-1995. NHIS (NHIC95); Centers for Disease Control/National Center for Health Statistics. Available at: http://www.cdc.gov/nchs/agingact.htm. Accessed June 2008.
6. Fried L.F., Shilpak M.G., Crump C., et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41 (2003) 1364-1372
7. Manjunath G., Tighiouart H., Coresh J., et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63 (2003) 1121-1129
8. Agostini J.V., Han L., and Tinetti M.E. The relationship between number of medications and weight loss or impaired balance in older adults. J Am Geriatr Soc 52 (2004) 1719-1723
9. Hug B.L., Witkowski D.J., Sox C.M., et al. Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney. Kidney Int 76 (2009) 1192-1198
10. Gill S.S., Mamdani M., Naglie G., et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 165 (2005) 808-813
11. Hayes T.L., Larimer N., Adami A., et al. Medication adherence in healthy elders: Small cognitive changes make a big difference. J Aging Health 21 (2009) 567-580
12. Turner B.J., Hollenbeak C., Weiner M.G., et al. Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiol Drug Saf 18 (2009) 672-681
13. Kennedy J., and Morgan S. Cost-related prescription nonadherence in the United States and Canada: A system-level comparison using the 2007 International Health Policy Survey in Seven Countries. Clin Ther 31 (2009) 213-219
14. Madden J.M., Graves A.J., Ross-Degnan A., et al. Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. JAMA 302 (2009) 1755-1756
15. Fick D.M., Cooper J.W., Wade W.E., et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 163 (2003) 2716-2724
16. Goulding M.R. Inappropriate medication prescribing for elderly ambulatory care patients. Arch Intern Med 164 (2004) 305-312
17. Budnitz D.S., Shehab N., Kegler S.R., et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 147 (2007) 755-765
18. Johnell K., and Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: A study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 10 (2007) 911-918
19. Kaufman D.W., Kelly J.P., Rosenberg L., et al. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 287 (2002) 337-344
20. Caskie G.I., Willis S.L., Warner Schaie K., et al. Congruence of medication information from a brown bag data collection and pharmacy records: Findings from the Seattle longitudinal study. Exp Aging Res 32 (2006) 79-103
21. Williams M.E., Pulliam C.C., Hunter R., et al. The short-term effect of interdisciplinary medication review on function and cost in ambulatory elderly people. J Am Geriatr Soc 52 (2004) 93-98
22. Rathore S.S., Mehta S.S., Boyko Jr. W.L., et al. Prescription medication use in older Americans: A national report card on prescribing. Fam Med 30 (1998) 733-739
23. Masoudi F.A., Rathore S.S., Wang Y., et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 110 (2004) 724-731
24. Kuijpers M.A., van Marum R.J., Egberts A.C., et al. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 65 (2008) 130-133
25. Stevens L.A., Viswanathan G., and Weiner D.E. Chronic kidney disease - Q2 and end-stage renal disease in the elderly population: Current prevalence, future projections, and clinical significance. ACKD 17 (2010) 293-301
26. Gill J., Malyuk R., Djurdjev O., et al. Use of GFR equations to adjust drug doses in an elderly multi-ethnic group-a cautionary tale. Nephrol Dial Transplant 22 (2007) 2894-2899
27. Fink J.C., Brown J., Hsu V.D., et al. CKD as an underrecognized threat to patient safety. Am J Kidney Dis 53 (2009) 681-688
28. Winkelmayer W.C., Fischer M.A., Schneeweiss S., et al. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis 46 (2005) 1080-1087
29. Elias M.F., Elias P.K., Seliger S.L., et al. Chronic kidney disease, creatinine and cognitive functioning. Nephrol Dial Transplant 24 (2009) 2446-2452
30. Hedayati S.S., Minhajuddin A.T., Toto R.D., et al. Prevalence of major depressive episode in CKD. Am J Kidney Dis 54 (2009) 424-432
31. Watnick S., Kirwin P., Mahnensmith R., et al. The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis 41 (2003) 105-110
32. Wilhelm-Leen E.R., Hall Y.N., Tamura M.K., et al. Frailty and chronic kidney disease: The Third National Health and Nutrition Evaluation Survey. Am J Med 122 (2009) 664-671 e2
33. Tinetti M.E., Bogardus Jr. S.T., and Agostini J.V. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 351 (2004) 2870-2874
34. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
35. Estacio R.O., Jeffers B.W., Hiatt W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New Engl J Med 338 (1998) 645-652
36. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330 (1994) 877-884
37. Lewis J.B., Berl T., Brain R.P., et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 34 (1999) 809-817
38. Ruggenenti P., Perna A., Loriga G., et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 365 (2005) 939-946
39. Schrier R.W., Estacio R.O., Esler A., et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002) 1086-1097
40. Wright Jr. J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288 (2002) 2421-2431
41. Snyder J.J., and Collins A.J. KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004. Am J Nephrol 30 (2009) 44-54
42. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289 (2003) 2560-2572
43. Peralta C.A., Hicks L.S., Chertow G.M., et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 45 (2005) 1119-1124
44. Winkelmayer W.C., Zhang Z., Shahinfar S., et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 29 (2006) 2210-2217
45. Perazella M.A., and Mahnensmith R.L. Hyperkalemia in the elderly: Drugs exacerbate impaired potassium homeostasis. J Gen Intern Med 12 (1997) 646-656
46. Bakris G.L., and Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?. Arch Intern Med 160 (2000) 685-693
47. Balamuthusamy S., Srinivasan L., Verma M., et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis. Am Heart J 155 (2008) 791-805
48. Einhorn L.M., Zhan M., Hsu V.D., et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169 (2009) 1156-1162
49. Pappoe L.S., and Winkelmayer W.C. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: Are they underutilized?. Drugs Aging 27 (2010) 87-94
50. Coca S.G., Krumholz H.M., Garg A.X., et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296 (2006) 1377-1384
51. Charytan D., and Kuntz R.E. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 70 (2006) 2021-2030
52. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
53. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
54. Ezekowitz J., McAlister F.A., Humphries K.H., et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44 (2004) 1587-1592
55. Winkelmayer W.C., Charytan D.M., Brookhart M.A., et al. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol 1 (2006) 796-801
56. Winkelmayer W.C., Levin R., and Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol 3 (2008) 1415-1422
57. Berger A.K., Duval S., Manske C., et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 153 (2007) 1064-1073
58. Tonelli M., Isles C., Craven T., et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112 (2005) 171-178
59. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57 (2004) 728-734
60. Sandhu S., Wiebe N., Fried L.F., et al. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
61. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009) 1395-1407
62. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
63. Moen M.F., Zhan M., Hsu V.D., et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 4 (2009) 1121-1127
64. Gerstein H.C., Miller M.E., Byrington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
65. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
66. Adhiyaman V., Asghar M., Oke A., et al. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 94 (2001) 512-514
67. Gooch K., Culleton B.F., Manns B.J., et al. NSAID use and progression of chronic kidney disease. Am J Med 120 (2007) 280 e1-e7
68. Winkelmayer W.C., Waikar S.S., Mogun H., et al. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med 121 (2008) 1092-1098
69. Laliberte M.C., Normandeau M., Lord A., et al. Use of over-the-counter medications and natural products in patients with moderate and severe chronic renal insufficiency. Am J Kidney Dis 49 (2007) 245-256
70. Winkelmayer W.C., Mehta J., and Wang P.S. Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney Int 72 (2007) 1388-1393
71. Mehrotra R., Kermah D.A., Salusky I.B., et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 76 (2009) 977-983
72. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
73. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
74. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009) 2019-2032
75. Blix H.S., Viktil K.K., Moger T.A., et al. Use of renal risk drugs in hospitalized patients with impaired renal function-an underestimated problem?. Nephrol Dial Transplant 21 (2006) 3164-3171
76. Corsonello A., Pedone C., Corica F., et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 165 (2005) 790-795
77. Salomon L., Deray G., Jaudon M.C., et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care 15 (2003) 331-335